NERV vs. BNTC, ORGS, VBIV, HUGE, KALA, NRSN, FLGC, GLTO, TCRT, and TLPH
Should you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include Benitec Biopharma (BNTC), Orgenesis (ORGS), VBI Vaccines (VBIV), FSD Pharma (HUGE), KALA BIO (KALA), NeuroSense Therapeutics (NRSN), Flora Growth (FLGC), Galecto (GLTO), Alaunos Therapeutics (TCRT), and Talphera (TLPH). These companies are all part of the "pharmaceutical preparations" industry.
Benitec Biopharma (NASDAQ:BNTC) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.
52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 4.3% of Benitec Biopharma shares are held by insiders. Comparatively, 6.4% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Benitec Biopharma has higher revenue and earnings than Minerva Neurosciences.
Benitec Biopharma currently has a consensus price target of $16.00, suggesting a potential upside of 131.88%. Minerva Neurosciences has a consensus price target of $11.00, suggesting a potential upside of 351.47%. Given Benitec Biopharma's higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than Benitec Biopharma.
In the previous week, Benitec Biopharma had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for Benitec Biopharma and 1 mentions for Minerva Neurosciences. Benitec Biopharma's average media sentiment score of 0.20 beat Minerva Neurosciences' score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the news media.
Benitec Biopharma has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500.
Benitec Biopharma's return on equity of 0.00% beat Minerva Neurosciences' return on equity.
Minerva Neurosciences received 166 more outperform votes than Benitec Biopharma when rated by MarketBeat users. However, 63.73% of users gave Benitec Biopharma an outperform vote while only 60.98% of users gave Minerva Neurosciences an outperform vote.
Summary
Benitec Biopharma beats Minerva Neurosciences on 8 of the 14 factors compared between the two stocks.
Get Minerva Neurosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Minerva Neurosciences Competitors List
Related Companies and Tools
